evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,749 questions · 17,858 findings · 1,266 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 4,359 · 24.4%GRADE not reported 2,348 · 13.1%Very low 4,634 · 25.9%Low 4,000 · 22.4%Moderate 2,052 · 11.5%High 465 · 2.6%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Methylphenidate vs placebo or no intervention

ADHD symptoms · Children and adolescents with ADHD

It is very uncertain whether methylphenidate changes ADHD symptoms: all parallel‐group trials and first‐period cross‐over… compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Methylphenidate vs placebo or no intervention

Proportion of participants with one or more serious adverse events · Children and adolescents with ADHD

It is very uncertain whether methylphenidate changes proportion of participants with one or more serious adverse events compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Methylphenidate vs placebo or no intervention

Adverse events considered non‐serious (penicillin versus doxycycline) · Children and adolescents with ADHD

It is very uncertain whether methylphenidate changes proportion of participants with one or more adverse events… compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Methylphenidate vs placebo or no intervention

General behaviour: all parallel‐group trials and first‐period cross‐over trials General behaviour rating scales (Teacher‐rated) · Children and adolescents with ADHD

It is very uncertain whether methylphenidate changes general behaviour: all parallel‐group trials and first‐period… compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Fibrin‐based haemostatic agents vs placebo or no intervention

Perioperative mortality · adults undergoing liver resection for cancer or benign disease

It is very uncertain whether fibrin‐based haemostatic agents changes perioperative mortality Median compared with no intervention or placebo (very low certainty).

1 finding from 1 review

Fibrin‐based haemostatic agents vs placebo or no intervention

Serious adverse events Median · adults undergoing liver resection for cancer or benign disease

It is very uncertain whether fibrin‐based haemostatic agents changes serious adverse events Median compared with no intervention or placebo (very low certainty).

1 finding from 1 review

Fibrin‐based haemostatic agents vs placebo or no intervention

Postoperative transfusion Median · adults undergoing liver resection for cancer or benign disease

It is very uncertain whether fibrin‐based haemostatic agents changes postoperative transfusion Median compared with no intervention or placebo (very low certainty).

1 finding from 1 review

Fibrin‐based haemostatic agents vs placebo or no intervention

Reoperation Median · adults undergoing liver resection for cancer or benign disease

It is very uncertain whether fibrin‐based haemostatic agents changes reoperation Median compared with no intervention or placebo (very low certainty).

1 finding from 1 review

Fibrin‐based haemostatic agents vs placebo or no intervention

Postoperative bile leak Median · adults undergoing liver resection for cancer or benign disease

It is very uncertain whether fibrin‐based haemostatic agents changes postoperative bile leak Median compared with no intervention or placebo (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Mortality ‐ total number · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in mortality ‐ total number compared with placebo/no intervention (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Hepatic encephalopathy · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin probably leads to lower hepatic encephalopathy ‐ total number compared with placebo/no intervention (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Non‐serious adverse events ‐ total number of particiapnts · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).

1 finding from 1 review